Our molecular docking studies suggest that promising selected compounds in head and neck cancer cells (HNSCC cells) could interact with human epidermal growth factor receptor 2 (HER2) and mesenchymal–epithelial transition factor (c-MET). The gene discussed is ERBB2; the disease is head and neck cancer.